Stephen Abreu has been appointed by the Board as Executive Director. He will lead the organization's overall strategy and ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, ...

Prior to ActiGraph, Christine was Head of Scientific Innovation at Biogen Healthcare Solutions, leading the clinical development and validation of Biogen’s digital medicine products (Software as ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unm ...

Biogen Inc. ( (BIIB)) has realeased its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is a leading biotechnology company that specializes ...

Bio­gen’s in­vestors are grow­ing rest­less. Wednes­day’s third-quar­ter earn­ings call checked most of the box­es for a suc­cess­ful re­port. The com­pa­ny raised its full-year ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...

Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth Quarterly Leqembi sales reached $67 million, beating estimates Cost cuts to drive high-teen percentage operating income boost ...